Follicular Non Hodgkin S Lymphoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for follicular non hodgkin s lymphoma. 31 active patents protecting 3 drugs from 2+ originators. First major cliff: 2029. Daily refresh.

3
Approved drugs
31
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered

Originators in Follicular Non Hodgkin S Lymphoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 19 patents Secura 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating follicular non hodgkin s lymphoma. Each bar = one year. Y-axis scaled to peak year (9 patents).

5
27
2
28
2
29
2
30
9
32
3
34
2
35
1
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Copiktra
DUVELISIB
 Secura 12 47 — 2029-01-05
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9216982 Copiktra method of use 75 2029-01-05
9216982 Copiktra method of use 75 2029-01-05
12213983 Copiktra method of use 75 2035-04-26
12213983 Copiktra method of use 75 2035-04-26
9840505 Copiktra method of use 68 2032-01-10
9840505 Copiktra method of use 68 2032-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8193182 Copiktra composition of matter 4 2032-09-24
8193182 Copiktra composition of matter 4 2032-09-24
RE46621 Copiktra composition of matter 4 2032-05-17
RE46621 Copiktra composition of matter 4 2032-05-17
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10022502 Decadron method of use 45 2034-06-22

Related